Gritstone Oncology has commenced dosing of patients in a Phase I/II clinical trial evaluating its personalised immunotherapy candidate GRANITE-001 in advanced solid tumours.

GRANITE-001 is designed to target and trigger significant T-cell response against the patient’s tumour-specific neoantigens, which will be detected using Gritstone’s EDGE artificial intelligence platform.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The therapeutic comprises a priming adenoviral vector and a monthly boosting with an RNA vector. Both vectors contain the same 20 patient-specific tumour-specific neoantigens.

Known as GO-004, the Phase I/II trial will assess GRANITE-001 plus immune checkpoint blockade to treat advanced solid tumours, including microsatellite stable colorectal cancer, gastroesophageal cancer, metastatic non-small cell lung cancer, and bladder cancer.

“Our team has impeccably executed the design, build-out, and implementation of this unique platform and our clinical trial collaborators have joined us in this exciting and innovative effort.”

Gritstone Oncology co-founder, president, and CEO Andrew Allen said: “With GRANITE-001, we are analysing the patient’s own tumour cell data through our artificial intelligence platform EDGE and using the identified neoantigens as the basis of a potent, virus-driven, personalised immunotherapy candidate which we manufacture in-house in large part.

“Our team has impeccably executed the design, build-out, and implementation of this unique platform and our clinical trial collaborators have joined us in this exciting and innovative effort to apply novel scientific insights to the treatment of this grim disease.”

Enrolment is ongoing for the trial’s Phase I portion, which involves two parts.

During part A, subjects will be administered with a full, fixed dose of adenovirus-based prime vector with escalating doses of RNA-based boost vector in combination with an intravenous anti-PD-1 therapy called nivolumab.

The part B will evaluate the prime and boost vectors at the selected dose plus nivolumab and also subcutaneous anti-CTLA-4 antibody ipilimumab.

Preliminary results from the trial are expected to be reported in the fourth quarter of this year.

GRANITE-001 has the US Food and Drug Administration (FDA) fast track designation for the treatment of MSS CRC.